This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furberg, C. D. Articles by Lichstein, E. Search for Related Content PubMed PubMed Citation Articles by Furberg, C. D. Articles by Lichstein, E.

Circulation, Vol 69, 761-765, Copyright © 1984 by American Heart Association

ARTICLES

Effect of propranolol in postinfarction patients with mechanical or electrical complications

CD Furberg, CM Hawkins and E Lichstein

In "post hoc" subgroup analyses, a simple classification system for patients, based on the presence or absence of findings indicative of electrical and/or mechanical complications early during short-term hospitalization, was applied to the data from the Beta-Blocker Heart Attack Trial (BHAT). In the largest subgroup of BHAT patients who had no reported complications, the 25 month mortality was low and the observed benefit of propranolol therapy small. Patients with electrical complications only had intermediate mortality and a pronounced effect of treatment was observed. Those with mechanical complications had the highest mortality and experienced an intermediate relative benefit of beta-blocker treatment. They also reported the most adverse effects. Post hoc analyses should always be interpreted cautiously. It is important to determine whether these findings are present in other completed beta-blocker trials. On the basis of these analyses alone it is suggested that the present practice of prescribing beta-blockers in postinfarction patients should not be altered.

This article has been cited by other articles:

				R. Ferrari, C. Ceconi, and G. Guardigli Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F7 - F10. [Abstract] [Full Text] [PDF]

				R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H16 - H21. [Abstract] [Full Text] [PDF]

				W. S. Aronow Management of the Elderly Person After Myocardial Infarction J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2004; 59(11): 1173 - 1185. [Abstract] [Full Text] [PDF]

				S. Sanal and W. S. Aronow Effect of an Educational Program on the Prevalence of Use of Antiplatelet Drugs, Beta Blockers, Angiotensin-Converting Enzyme Inhibitors, Lipid-Lowering Drugs, and Calcium Channel Blockers Prescribed During Hospitalization and at Hospital Discharge in Patients With Coronary Artery Disease J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2003; 58(11): M1046 - 1048. [Abstract] [Full Text] [PDF]

				R. Ferrari, S. Censi, F. Mastrorilli, and A. Boraso Prognostic benefits of heart rate reduction in cardiovascular disease Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G10 - G14. [Abstract] [PDF]

				W. S. Aronow Guest Editorial: What Is the Appropriate Treatment of Hypertension in Elders? J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2002; 57(8): M483 - 486. [Full Text] [PDF]

				F. A. Spencer, T. E. Meyer, J. M. Gore, and R. J. Goldberg Heterogeneity in the Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Heart Failure: The National Registry of Myocardial Infarction Circulation, June 4, 2002; 105(22): 2605 - 2610. [Abstract] [Full Text] [PDF]

				S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450. [PDF]

				X. Jouven, M. Zureik, M. Desnos, C. Guerot, and P. Ducimetiere Resting heart rate as a predictive risk factor for sudden death in middle-aged men Cardiovasc Res, May 1, 2001; 50(2): 373 - 378. [Abstract] [Full Text] [PDF]

				A. J. Moss Implantable Cardioverter Defibrillator Therapy : The Sickest Patients Benefit the Most Circulation, April 11, 2000; 101(14): 1638 - 1640. [Full Text] [PDF]

				K S Spargias, A S Hall, D C Greenwood, and S G Ball beta Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study Heart, January 1, 1999; 81(1): 25 - 32. [Abstract] [Full Text]

				G. Neumayr, J. Ganzer, L. Kober, C. Torp-Pedersen, and J. Carlsen Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction N. Engl. J. Med., June 6, 1996; 334(23): 1546 - 1546. [Full Text]

				D G Julian Secondary prophylaxis after myocardial infarction BMJ, January 7, 1995; 310(6971): 61 - 61. [Full Text]

				S. Yusuf, J. Wittes, J. Probstfield, and H. A. Tyroler Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials JAMA, July 3, 1991; 266(1): 93 - 98. [Abstract] [PDF]

				J. J. Goldberger, H. B. Peled, J. A. Stroh, M. N. Cohen, and W. H. Frishman Prognostic Factors in Acute Pulmonary Edema Arch Intern Med, March 1, 1986; 146(3): 489 - 493. [Abstract] [PDF]

				J. T. BIGGER JR. and J. COROMILAS How Do Beta-Blockers Protect After Myocardial Infarction? Ann Intern Med, August 1, 1984; 101(2): 256 - 258. [Abstract] [PDF]